Indication intelligence, analysis and sector perception

Ocata Therapeutics (OCAT) Acquisition, tender offer expires - Today

February 9, 2016 1:35pm

Astellas has extended, through its indirect wholly-owned subsidiary Laurel Acquisition Inc., the offering period of the tender offer to purchase all issued and outstanding shares of common stock of OCAT for a price of US $8.50 per share, net to the holder in cash until 5:00 pm, U.S. ET, on 2/9/16.

The tender offer, as previously extended, was scheduled to expire at 5:00 pm, U.S. ET, on January 21, 2016. The further extension of the tender offer will allow OCAT's stockholders additional time to tender their shares into the Tender Offer.

All terms and conditions of the tender offer remain unchanged during the extended offering period.

Leaves a lot to say about this board of directors (BOD) and CEO representation of their shareholders … there is currently and will be a backlash about their individual perception … if they are considered to represent other companies <as BOD members> and their stakeholders!

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

1 hour 49 min ago
RegMed Investors (RMi) Closing Bell: this week’s trend is an admission that the sector is without pricing sustainability suppressing a value directional

10 hours 50 min ago
RegMed Investors’ (RMi) pre-open: the down draft doesn’t seem to be over

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.